PubRank

Peter S Nelson

Author PubWeight™ 258.03‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008 33.65
2 Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008 11.43
3 Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008 10.66
4 Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012 9.93
5 Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003 8.11
6 Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007 5.97
7 Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010 5.77
8 Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 2012 4.67
9 Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011 4.65
10 A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A 2008 3.83
11 Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A 2011 3.54
12 Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006 3.32
13 Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009 3.24
14 Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 2012 3.21
15 The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 2010 3.09
16 The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res 2006 3.07
17 A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 2013 2.94
18 A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat Biotechnol 2011 2.91
19 A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A 2006 2.89
20 Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One 2011 2.88
21 Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 2011 2.86
22 Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 2011 2.81
23 Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res 2013 2.70
24 Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 2006 2.57
25 Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis. J Clin Oncol 2006 2.56
26 LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate 2003 2.28
27 Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res 2014 2.15
28 Supervised normalization of microarrays. Bioinformatics 2010 2.00
29 Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate. BMC Genomics 2008 1.95
30 Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab 2008 1.78
31 Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol 2009 1.75
32 Delayed dark adaptation in 11-cis-retinol dehydrogenase-deficient mice: a role of RDH11 in visual processes in vivo. J Biol Chem 2005 1.58
33 Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma. BJU Int 2011 1.48
34 Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology 2009 1.46
35 Phenotypic analysis of mice lacking the Tmprss2-encoded protease. Mol Cell Biol 2006 1.44
36 Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res 2009 1.42
37 Biochemical properties of purified human retinol dehydrogenase 12 (RDH12): catalytic efficiency toward retinoids and C9 aldehydes and effects of cellular retinol-binding protein type I (CRBPI) and cellular retinaldehyde-binding protein (CRALBP) on the oxidation and reduction of retinoids. Biochemistry 2005 1.42
38 Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis 2007 1.41
39 Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. Am J Pathol 2011 1.33
40 Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Res 2008 1.32
41 Suppression of growth and tumorigenicity in the prostate tumor cell line M12 by overexpression of the transcription factor SOX9. Oncogene 2004 1.31
42 The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol 2012 1.29
43 Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol 2012 1.25
44 Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts. PLoS One 2012 1.24
45 Analysis of testosterone and dihydrotestosterone from biological fluids as the oxime derivatives using high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2007 1.24
46 Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS One 2013 1.23
47 Molecular characterization of prostatic small-cell neuroendocrine carcinoma. Prostate 2003 1.22
48 Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites. Am J Physiol Endocrinol Metab 2005 1.21
49 Conserved gene expression programs integrate mammalian prostate development and tumorigenesis. Cancer Res 2009 1.20
50 Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res 2006 1.19
51 PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Res 2004 1.15
52 CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate 2010 1.14
53 Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression. Cancer Res 2011 1.14
54 Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol 2013 1.14
55 Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol Oncol 2009 1.14
56 Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol 2010 1.12
57 CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker. Mod Pathol 2010 1.11
58 The effects of aging on the molecular and cellular composition of the prostate microenvironment. PLoS One 2010 1.10
59 Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect. Clin Cancer Res 2010 1.09
60 Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors. Prostate 2004 1.09
61 Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res 2004 1.09
62 Tissue-specific consequences of cyclin D1 overexpression in prostate cancer progression. Cancer Res 2007 1.08
63 Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention. Cancer Res 2010 1.07
64 Characterization of chemical constituents in Scutellaria baicalensis with antiandrogenic and growth-inhibitory activities toward prostate carcinoma. Clin Cancer Res 2005 1.06
65 Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo. Cancer Lett 2006 1.06
66 VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer. Cancer Discov 2012 1.06
67 Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial. J Clin Endocrinol Metab 2010 1.04
68 Evidence that the human gene for prostate short-chain dehydrogenase/reductase (PSDR1) encodes a novel retinal reductase (RalR1). J Biol Chem 2002 1.03
69 Gene expression profiling in the developing prostate. Differentiation 2008 1.02
70 Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol 2010 1.02
71 Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes. Neoplasia 2006 1.02
72 Prostate tissue androgens: history and current clinical relevance. Urology 2008 1.02
73 The contributions of normal variation and genetic background to mammalian gene expression. Genome Biol 2006 1.01
74 Mitochondrial DNA mutation stimulates prostate cancer growth in bone stromal environment. Prostate 2009 1.01
75 ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21. Cancer Res 2010 1.01
76 AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer. Neoplasia 2013 1.00
77 Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1. Oncogene 2003 1.00
78 Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15. Clin Cancer Res 2007 1.00
79 Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries. Prostate 2005 0.99
80 TMPRSS2 is a host factor that is essential for pneumotropism and pathogenicity of H7N9 influenza A virus in mice. J Virol 2014 0.99
81 Bayesian integrated functional analysis of microarray data. Bioinformatics 2004 0.99
82 Cellular senescence and cancer chemotherapy resistance. Drug Resist Updat 2012 0.99
83 Digital expression profiles of the prostate androgen-response program. J Steroid Biochem Mol Biol 2002 0.98
84 A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49. Am J Pathol 2002 0.97
85 Gene expression profiling of the human prostate androgen response program. J Androl 2002 0.97
86 The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells. Prostate 2010 0.96
87 Low-fat, low-glycemic load diet and gene expression in human prostate epithelium: a feasibility study of using cDNA microarrays to assess the response to dietary intervention in target tissues. Cancer Epidemiol Biomarkers Prev 2007 0.95
88 Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma. Int J Cancer 2005 0.94
89 Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation. J Clin Endocrinol Metab 2013 0.93
90 Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells. Prostate 2005 0.93
91 CaSm-mediated cellular transformation is associated with altered gene expression and messenger RNA stability. Cancer Res 2005 0.93
92 Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum. J Steroid Biochem Mol Biol 2013 0.92
93 PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality. Mol Cancer Res 2013 0.92
94 KLK31P is a novel androgen regulated and transcribed pseudogene of kallikreins that is expressed at lower levels in prostate cancer cells than in normal prostate cells. Prostate 2006 0.92
95 Collagen extracts derived from young and aged mice demonstrate different structural properties and cellular effects in three-dimensional gels. J Gerontol A Biol Sci Med Sci 2010 0.91
96 Prostate cancer cell phenotypes based on AGR2 and CD10 expression. Mod Pathol 2013 0.90
97 Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition. J Natl Cancer Inst 2002 0.90
98 Expressed sequence tag profiling identifies developmental and anatomic partitioning of gene expression in the mouse prostate. Genome Biol 2003 0.90
99 A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray. Adv Anat Pathol 2013 0.90
100 Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression. Cancer Res 2009 0.90
101 Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases. Prostate 2013 0.89
102 Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer. Proteomics Clin Appl 2011 0.89
103 Identification of androgen-coregulated protein networks from the microsomes of human prostate cancer cells. Genome Biol 2003 0.89
104 Molecular effects of the herbal compound PC-SPES: identification of activity pathways in prostate carcinoma. Cancer Res 2002 0.89
105 Single cell transcriptomic analysis of prostate cancer cells. BMC Mol Biol 2013 0.89
106 WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence. Clin Cancer Res 2008 0.88
107 Regulation of global gene expression in the bone marrow microenvironment by androgen: androgen ablation increases insulin-like growth factor binding protein-5 expression. Prostate 2007 0.88
108 The role of cyclooxygenase-2 inhibition for the prevention and treatment of prostate carcinoma. Clin Prostate Cancer 2003 0.88
109 HE3235 inhibits growth of castration-resistant prostate cancer. Neoplasia 2009 0.87
110 A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors. PLoS One 2013 0.86
111 Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality. Prostate 2013 0.86
112 Human prostate epithelial cell-type cDNA libraries and prostate expression patterns. Prostate 2002 0.86
113 Genetic background influences murine prostate gene expression: implications for cancer phenotypes. Genome Biol 2007 0.86
114 Molecular pathways: involving microenvironment damage responses in cancer therapy resistance. Clin Cancer Res 2012 0.86
115 Association of megalin genetic polymorphisms with prostate cancer risk and prognosis. Clin Cancer Res 2008 0.86
116 Testosterone regulates tight junction proteins and influences prostatic autoimmune responses. Horm Cancer 2011 0.85
117 Isolation and characterization of human and mouse WDR19,a novel WD-repeat protein exhibiting androgen-regulated expression in prostate epithelium. Genomics 2003 0.84
118 Prostate cancer-associated gene expression alterations determined from needle biopsies. Clin Cancer Res 2009 0.83
119 Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer. Cancer 2007 0.83
120 Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment. Clin Exp Metastasis 2013 0.83
121 Transforming Growth Factor-{beta}-Stimulated Clone-22 Is an Androgen-Regulated Gene That Enhances Apoptosis in Prostate Cancer following Insulin-Like Growth Factor-I Receptor Inhibition. Clin Cancer Res 2009 0.83
122 cDNA microarray analysis identifies genes induced in common by peptide growth factors and androgen in human prostate epithelial cells. Mol Carcinog 2005 0.82
123 Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate. Am J Pathol 2005 0.82
124 Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer. BMC Cancer 2010 0.82
125 Merkel cell polyomavirus is not detected in prostate cancers, surrounding stroma, or benign prostate controls. J Clin Virol 2009 0.80
126 Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo. Oncogene 2002 0.80
127 Genome interrupted: sequencing of prostate cancer reveals the importance of chromosomal rearrangements. Genome Med 2011 0.80
128 Integrative analysis of N-linked human glycoproteomic data sets reveals PTPRF ectodomain as a novel plasma biomarker candidate for prostate cancer. J Proteome Res 2012 0.80
129 Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial. J Clin Endocrinol Metab 2012 0.80
130 Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer. Cancer Lett 2008 0.79
131 The monoamine oxidase A gene promoter repeat and prostate cancer risk. Prostate 2012 0.79
132 Differential expression of the alpha2 chain of the interleukin-13 receptor in metastatic human prostate cancer ARCaPM cells. Prostate 2010 0.78
133 Intraprostatic steroidogenic enzymes - letter. Cancer Res 2010 0.78
134 Isolation and characterization of the murine prostate short-chain dehydrogenase/reductase 1 (Psdr1) gene, a new member of the short-chain steroid dehydrogenase/reductase family. Gene 2002 0.77
135 The role of tissue microarrays in prostate cancer biomarker discovery. Adv Anat Pathol 2007 0.77
136 Characterization and comparative analyses of transcriptomes from the normal and neoplastic human prostate. Prostate 2004 0.77
137 Differential expression of bikunin (HAI-2/PB), a proposed mediator of glioma invasion, by demethylation treatment. J Neurooncol 2003 0.76
138 Microarray analysis and tumor classification. N Engl J Med 2006 0.75
139 Leveraging the species barrier to advance cancer therapy. Nat Genet 2013 0.75
140 Editorial comment. Urology 2012 0.75
141 Fourth joint meeting of the American Urological Association and the Japanese Urological Association Specialty Society program at the 104th annual meeting of the American Urological Association at Chicago 2009. Int J Urol 2009 0.75
142 Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort. Am J Surg Pathol 2016 0.75
143 Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. J Urol 2004 0.75
144 Integrative Clinical Genomics of Advanced Prostate Cancer. Cell 2015 0.75
145 Genomic predictors of prostate cancer therapy outcomes. Expert Rev Mol Diagn 2010 0.75